	US 11,911,413 B2
	Methods and compositions for the treatment of pain and/or inflammation
Peter Ghosh, Fairlight (AU); and Jack Edelman, Subiaco (AU)
Assigned to Proteobioactives Pty Limited, Fairlight (AU)
Appl. No. 16/970,049
Filed by Proteobioactives Pty Limited, Fairlight (AU); and Nancy Wilson-Ghosh, Fairlight (AU)
PCT Filed Feb. 15, 2019, PCT No. PCT/AU2019/050119 § 371(c)(1), (2) Date Aug. 14, 2020, PCT Pub. No. WO2019/157560, PCT Pub. Date Aug. 22, 2019.
Claims priority of application No. 2018900504 (AU), filed on Feb. 16, 2018.
Prior Publication US 2021/0093658 A1, Apr. 1, 2021
Int. Cl. A61K 31/737 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 31/196 (2006.01); A61K 31/365 (2006.01); A61K 31/415 (2006.01); A61K 31/42 (2006.01); A61K 31/444 (2006.01); A61P 19/02 (2006.01); A61P 29/00 (2006.01)

CPC A61K 31/737 (2013.01) [A61K 9/0053 (2013.01); A61K 9/4816 (2013.01); A61K 31/196 (2013.01); A61K 31/365 (2013.01); A61K 31/415 (2013.01); A61K 31/42 (2013.01); A61K 31/444 (2013.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01)]

15 Claims

1. A pharmaceutical or veterinary composition for oral administration comprising a therapeutically effective amount of at least one coxib and a therapeutically effective amount of unfractionated sodium pentosan polysulfate contained in a hydroxy propyl methylcellulose capsule, with the proviso that the composition does not include a penetration enhancer for increasing bioavailability of the unfractionated sodium pentosan polysulfate.